Literature DB >> 24510366

Enhanced anti-tumor activity of triptolide in combination with irradiation for the treatment of oral cancer.

Yuan-Wu Chen1, Gu-Jiun Lin2, Dong-Yuan Hueng3, Shing-Hwa Huang2, Wei-Tso Chia4, Yi-Shing Shieh1, Kuo-Hsing Ma2, Huey-Kang Sytwu5.   

Abstract

Advanced oral cancer has a poor prognosis because of the lack of an effective treatment. We explored the efficiency of combined treatment with triptolide and ionizing radiation for treating oral cancer. Human tongue cancer cells were treated with triptolide, ionizing radiation, or triptolide plus ionizing radiation. Cell proliferation, cell cycle arrest, and apoptotic influences were analyzed by FACS and immunohistochemistry. Tumor potency was examined in an in vivo human tongue cancer cells xenograft mouse model. Our results demonstrated that triptolide caused a marked reduction in colony number that was further enhanced with increasing doses of ionizing radiation. Triptolide increased apoptosis and decreased the expression of anti-apoptotic proteins. In vivo, combination treatment synergistically reduced tumor weight and volume possibly via the induction of apoptosis and reduction in anti-apoptotic protein expression. In conclusion, triptolide plus ionizing radiation treatment had synergistic anti-tumor effects, especially in vivo, and may be a promising combined modality therapy for advanced oral cancer. Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24510366     DOI: 10.1055/s-0033-1360315

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  7 in total

1.  Triptolide enhances the tumoricidal activity of TRAIL against renal cell carcinoma.

Authors:  Erik L Brincks; Tamara A Kucaba; Britnie R James; Katherine A Murphy; Kathryn L Schwertfeger; Veena Sangwan; Sulagna Banerjee; Ashok K Saluja; Thomas S Griffith
Journal:  FEBS J       Date:  2015-10-18       Impact factor: 5.542

Review 2.  Targets and molecular mechanisms of triptolide in cancer therapy.

Authors:  Cuicui Meng; Hongcheng Zhu; Hongmei Song; Zhongming Wang; Guanhong Huang; Defan Li; Zhaoming Ma; Jianhua Ma; Qin Qin; Xinchen Sun; Jianxin Ma
Journal:  Chin J Cancer Res       Date:  2014-10       Impact factor: 5.087

3.  Triptolide inhibits cell proliferation and tumorigenicity of human neuroblastoma cells.

Authors:  Xiaomin Yan; Xiao-Xue Ke; Hailong Zhao; Mengying Huang; Renjian Hu; Hongjuan Cui
Journal:  Mol Med Rep       Date:  2014-10-29       Impact factor: 2.952

4.  Triptolide Combined with Radiotherapy for the Treatment of Nasopharyngeal Carcinoma via NF-κB-Related Mechanism.

Authors:  Weiying Zhang; Min Kang; Tingting Zhang; Bo Li; Xueyin Liao; Rensheng Wang
Journal:  Int J Mol Sci       Date:  2016-12-19       Impact factor: 5.923

Review 5.  Compounds From Celastraceae Targeting Cancer Pathways and Their Potential Application in Head and Neck Squamous Cell Carcinoma: A Review.

Authors:  Camila Hernandes; Ana Maria Soares Pereira; Patricia Severino
Journal:  Curr Genomics       Date:  2017-02       Impact factor: 2.236

6.  Anti-oral cancer effects of triptolide by downregulation of DcR3 in vitro, in vivo, and in preclinical patient-derived tumor xenograft model.

Authors:  Cheng-Yu Yang; Chih-Kung Lin; Cheng-Chih Hsieh; Chang-Huei Tsao; Chun-Shu Lin; Bo Peng; Yen-Tzu Chen; Chun-Chieh Ting; Wei-Chin Chang; Gu-Jiun Lin; Huey-Kang Sytwu; Yuan-Wu Chen
Journal:  Head Neck       Date:  2018-12-10       Impact factor: 3.147

7.  Triptolide represses oral cancer cell proliferation, invasion, migration, and angiogenesis in co-inoculation with U937 cells.

Authors:  Cheng-Yu Yang; Chih-Kung Lin; Gu-Jiun Lin; Cheng-Chih Hsieh; Shing-Hwa Huang; Kuo-Hsing Ma; Yi-Shing Shieh; Huey-Kang Sytwu; Yuan-Wu Chen
Journal:  Clin Oral Investig       Date:  2016-04-13       Impact factor: 3.573

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.